Genomic and Clinical Analysis of Influenza A in Hospitalized Adults, 2019–2024: Exploratory Evidence on Neuraminidase and Polymerase Acidic Protein Mutation‐Outcome Associations From a Single Center
5 affiliations
- 1Department of Emergency, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
- 2Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
- 3Department of Infectious Diseases, Shanghai East Hospital, School of Medicine Tongji University Shanghai China
- 4Clinical Research Center, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
- 5Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases Shanghai China
Abstract
Background: Antivirals are widely used to treat influenza, but potential resistance mutations remain a major challenge, and clinical data on key resistance mutations are limited.
Methods: We conducted a retrospective cohort study of 765 adults with RT‐PCR‐confirmed influenza A admitted to Ruijin Hospital, Shanghai, between 2019 and 2024 to determine whether specific NA/PA mutations are associated with severe outcomes or prolonged length of stay (LOS) when analyzed alongside key host factors. PA and NA sequences were obtained and linked to the clinical cohort for mutation‐clinical outcome analyses. Multiple testing was addressed by controlling the false discovery rate using the Benjamini–Hochberg procedure.
Results: Among 765 inpatients with influenza A virus infection, the median age was 68 years; 5.0% were severe disease and 9.9% died. Older age, higher CURB‐65 score, and bacterial/fungal co‐infection were the main correlates of mortality, whereas antiviral regimen and Ct value were not independently associated with mortality or severe outcomes. Adjusted observational analyses showed a lower estimate for severe disease with baloxavir but no association with in‐hospital death. Major high‐level resistance mutations were absent; detected NA/PA mutations showed no robust association with severe disease or mortality. PA‐F105L showed an exploratory association with longer LOS, but this finding was attenuated after adjustment and was confounded by clade and calendar period.
Conclusions: Clinical outcomes were driven mainly by host factors and admission severity. Detected NA/PA mutations were not robustly associated with severe outcomes, while high‐level resistance could not be assessed; PA‐F105L–LOS association requires phenotypic and external validation.
Related
- Intranasal adenoviral neuraminidase vaccine induces local and systemic immunity and homosubtypic protection against influenza A viruses
- Repositioning antiviral phytoconstituents as broad-spectrum inhibitors of influenza A neuraminidase and human metapneumovirus fusion protein
- Clinical Relevance of Multiplex PCR for Respiratory Pathogens in Hospitalized Adults with Influenza-Like Illness
- Genome‐Wide Association Studies of Hospitalized Influenza Identify Four Risk Loci and Reveal Shared and Unique Genetic Factors Compared With COVID‐19
- Influenza A Virus RNA Polymerase Is Enriched on the Chromatin of Innate Immune Response Genes
BibTeX
@article{feng2026genomic,
title = {{Genomic and Clinical Analysis of Influenza A in Hospitalized Adults, 2019–2024: Exploratory Evidence on Neuraminidase and Polymerase Acidic Protein Mutation‐Outcome Associations From a Single Center}},
author = {Anqi Feng and Wei Tan and Wenxin Xu and Xinxin Zhang and Dong Wei and Zhitao Yang},
journal = {Influenza and Other Respiratory Viruses},
year = {2026},
month = oct,
doi = {10.1111/irv.70331},
url = {https://doi.org/10.1111/irv.70331},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Genomic and Clinical Analysis of Influenza A in Hospitalized Adults, 2019–2024: Exploratory Evidence on Neuraminidase and Polymerase Acidic Protein Mutation‐Outcome Associations From a Single Center
AU - Anqi Feng
AU - Wei Tan
AU - Wenxin Xu
AU - Xinxin Zhang
AU - Dong Wei
AU - Zhitao Yang
PY - 2026
DA - 2026/10/27
JO - Influenza and Other Respiratory Viruses
DO - 10.1111/irv.70331
UR - https://doi.org/10.1111/irv.70331
AB - Background: Antivirals are widely used to treat influenza, but potential resistance mutations remain a major challenge, and clinical data on key resistance mutations are limited. Methods: We conducted a retrospective cohort study of 765 adults with RT‐PCR‐confirmed influenza A admitted to Ruijin Hospital, Shanghai, between 2019 and 2024 to determine whether specific NA/PA mutations are associated with severe outcomes or prolonged length of stay (LOS) when analyzed alongside key host factors. PA and NA sequences were obtained and linked to the clinical cohort for mutation‐clinical outcome analyses. Multiple testing was addressed by controlling the false discovery rate using the Benjamini–Hochberg procedure. Results: Among 765 inpatients with influenza A virus infection, the median age was 68 years; 5.0% were severe disease and 9.9% died. Older age, higher CURB‐65 score, and bacterial/fungal co‐infection were the main correlates of mortality, whereas antiviral regimen and Ct value were not independently associated with mortality or severe outcomes. Adjusted observational analyses showed a lower estimate for severe disease with baloxavir but no association with in‐hospital death. Major high‐level resistance mutations were absent; detected NA/PA mutations showed no robust association with severe disease or mortality. PA‐F105L showed an exploratory association with longer LOS, but this finding was attenuated after adjustment and was confounded by clade and calendar period. Conclusions: Clinical outcomes were driven mainly by host factors and admission severity. Detected NA/PA mutations were not robustly associated with severe outcomes, while high‐level resistance could not be assessed; PA‐F105L–LOS association requires phenotypic and external validation.
SN - 1750-2640
SN - 1750-2659
ER -